Sinakhanim Huseynzada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sinakhanim Huseynzada has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ali Balci
Department of Radiology, Dokuz Eylul University School of Medicine, Izmir, Türkiye
1 shared publication - Aydan Köken Avşar
Dokuz Eylul University School of Medicine
1 shared publication - Aynur Aliyeva
Neuroscience Doctoral Program, Yeditepe University, Istanbul, Turkey
1 shared publication - Bayram Yilmaz
Faculty of Medicine, Department of Physiology Yeditepe University Istanbul Türkiye
1 shared publication - Farid Hajiyev
Division of Gastroenterology, Dokuz Eylül University, Faculty of Medicine, Izmir, Turkey
1 shared publication - Fatos Onen
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
1 shared publication
Latest Publications
- 25 November 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (2) , 1251-1261
The role of Single-sited combined nasal and uvulopalatopharyngoplasty surgery in obstructive sleep apnea syndrome: integrating anatomy-based selection with advanced statistical outcomes
Purpose To evaluate the clinical efficacy and outcomes of a single-stage surgical approach combining nasal surgery and uvulopalatopharyngoplasty (UPPP) in patients with obstructive sleep apnea syndrome (OSAS) and nasal obstruction. Methods Fifty adult patients with OSAS and anatomical nasal obstruction underwent single-stage UPPP with septoplasty and conchoplasty. Pre- and postoperative evaluations included subjective symptom scoring, polysomnography, anterior active rhinomanometry (AAR), and the SF-36 quality of life questionnaire. Surgical success was defined as ≥ 50% reduction in apnea-hypopnea index (AHI) and postoperative AHI < 20. Patients were classified using the Friedman anatomical staging system. Statistical analyses included paired t-tests, ANCOVA, logistic regression, effect sizes (Cohen’s d), and Bonferroni correction. Results Mean AHI improved significantly from 50.1 ± 17.4 to 18.8 ± 19.6 events/hour (p < .001). Surgical success and response rates were 62.0% and 72.0%, respectively. Stage-specific success was highest in Stage I (68.4%) and lowest in Stage III (46.2%). Significant reductions were observed in nasal resistance (from 0.46 ± 0.08 to 0.27 ± 0.06 Pa/cm³/s; p < .001) and ESS scores (from 11.2 ± 3.7 to 5.8 ± 2.7; p < .001). All SF-36 domains improved postoperatively. Effect sizes for key parameters were large (Cohen’s d > 1.0), and all p-values remained significant after adjustment. Conclusion Single-stage UPPP combined with nasal surgery is a safe and effective treatment for OSAS patients with nasal obstruction. Anatomical staging plays a key role in predicting surgical outcomes. Objective airflow, sleep indices, and quality-of-life measures confirm the clinical value of this integrated approach.
- 25 November 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (2) , 1251-1261
The role of Single-sited combined nasal and uvulopalatopharyngoplasty surgery in obstructive sleep apnea syndrome: integrating anatomy-based selection with advanced statistical outcomes
Purpose To evaluate the clinical efficacy and outcomes of a single-stage surgical approach combining nasal surgery and uvulopalatopharyngoplasty (UPPP) in patients with obstructive sleep apnea syndrome (OSAS) and nasal obstruction. Methods Fifty adult patients with OSAS and anatomical nasal obstruction underwent single-stage UPPP with septoplasty and conchoplasty. Pre- and postoperative evaluations included subjective symptom scoring, polysomnography, anterior active rhinomanometry (AAR), and the SF-36 quality of life questionnaire. Surgical success was defined as ≥ 50% reduction in apnea-hypopnea index (AHI) and postoperative AHI < 20. Patients were classified using the Friedman anatomical staging system. Statistical analyses included paired t-tests, ANCOVA, logistic regression, effect sizes (Cohen’s d), and Bonferroni correction. Results Mean AHI improved significantly from 50.1 ± 17.4 to 18.8 ± 19.6 events/hour (p < .001). Surgical success and response rates were 62.0% and 72.0%, respectively. Stage-specific success was highest in Stage I (68.4%) and lowest in Stage III (46.2%). Significant reductions were observed in nasal resistance (from 0.46 ± 0.08 to 0.27 ± 0.06 Pa/cm³/s; p < .001) and ESS scores (from 11.2 ± 3.7 to 5.8 ± 2.7; p < .001). All SF-36 domains improved postoperatively. Effect sizes for key parameters were large (Cohen’s d > 1.0), and all p-values remained significant after adjustment. Conclusion Single-stage UPPP combined with nasal surgery is a safe and effective treatment for OSAS patients with nasal obstruction. Anatomical staging plays a key role in predicting surgical outcomes. Objective airflow, sleep indices, and quality-of-life measures confirm the clinical value of this integrated approach.
- Open Access
- 12 May 2023
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (2) , 50-56
The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn’s disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results. Cite this article as: Huseynzada S, Yüce Inel T, Hajiyev F, et al. The effect of vedolizumab on spondyloarthritis symptoms in a cohort of inflammatory bowel disease patients. Eur J Rheumatol 2023;10(2):50-56.
- 12 May 2023
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 10 (2) , 50-56
Open AccessThe Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn’s disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results. Cite this article as: Huseynzada S, Yüce Inel T, Hajiyev F, et al. The effect of vedolizumab on spondyloarthritis symptoms in a cohort of inflammatory bowel disease patients. Eur J Rheumatol 2023;10(2):50-56.